Pooled Umbilical Cord Blood NK Cells Enhance Antibody ADCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic antibodies often exhibit limited efficacy in treating cancers and other diseases due to suboptimal activation of natural killer (NK) cells, which are crucial for antibody-dependent cell-mediated cytotoxicity (ADCC).
Innovation Solution
The method involves combining therapeutic antibodies with alloreactive NK cells obtained from pooled umbilical cord blood units (UCBs), which are amplified and activated to enhance ADCC efficacy. This approach allows for the simultaneous, separate, or sequential administration of NK cells and therapeutic antibodies to increase treatment efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are used alone, then the treatment can be administered simply, but the efficacy is limited due to suboptimal activation of NK cells
Solution Approach 1:
The patent combines therapeutic antibodies with alloreactive NK cells from pooled umbilical cord blood units to create a composite treatment composition. This merging of two therapeutic agents (antibodies and NK cells) enhances ADCC-mediated tumor cell killing efficacy while managing the complexity through standardized pooling procedures
2Quantity of substance
If NK cells are pooled from multiple umbilical cord blood units, then the quantity and diversity of NK cells increase, but the manufacturing process complexity increases
Solution Approach 1:
The patent segments the NK cell production process into distinct stages: individual umbilical cord blood unit processing, NK cell isolation from each unit, and subsequent pooling of standardized NK cell products. This segmentation allows for quality control at each stage while achieving the desired quantity and diversity in the final pooled product
Solution Approach 2:
The patent applies parameter changes by standardizing the pooling process based on HLA genotype matching criteria and NK cell activation status. By defining specific parameters for pooling (HLA compatibility, cell viability, activation markers), the manufacturing complexity is managed while ensuring consistent quality and efficacy across different pooled products
3Reliability
If NK cells are amplified and activated, then the ADCC activity increases, but the treatment time and process complexity increase
Solution Approach 1:
The patent applies preliminary action by pre-amplifying and pre-activating NK cells from umbilical cord blood units before pooling and clinical administration. This advance preparation ensures that NK cells are in an optimal activated state with enhanced ADCC capability when administered with therapeutic antibodies, reducing the need for prolonged in-vivo activation time
Solution Approach 2:
The patent uses cytokines and activation reagents as intermediaries to stimulate NK cell activation and amplification during the preparation phase. These intermediary substances facilitate rapid NK cell activation and proliferation in vitro, achieving the desired ADCC enhancement without requiring extended treatment time in the patient
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of amplified and activated alloreactive NK cells with therapeutic antibodies significantly enhances ADCC, leading to improved treatment outcomes for cancers and other diseases by increasing the cytotoxic activity of NK cells.
Implementation Method 1
NK cell recognition of an antibody-coated target cell, particularly by recognizing the NK cell Fc receptor, CD16 (FcγRIIIa), results in rapid NK cell activation and degranulation
Implementation Method 2
The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (NK cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled NK cells from umbilical cord blood units (UCBs), preferably alloreactive NK cells, in combination with a therapeutic antibody
Data Source
AI summary
The invention relates to the field of cell therapy, particularly NK cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (NK cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled NK cells from umbilical cord blood units (UCBs), preferably alloreactive NK cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. The present invention relates to said composition as a pharmaceutical composition, preferably for its use for the treatment of a disease in a human subject in need thereof, preferably wherein said disease is a cancer, infectious or immune disease. Finally, the present invention is also directed to a method of treatment of a disease in a human subject in need thereof, comprising the administering to said subject said pooled NK cells from UCBs, preferably alloreactive, in combination with a therapeutic antibody which can be bound to said NK cells.